

Tamrintamab

Cat. No.:	HY-P99506
CAS No.:	2148325-59-9
Target:	ADC Antibody
Pathway:	Antibody-drug Conjugate/ADC Related
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Tamrintamab (SC-003 mAb, SC-Mab003, SC34.28ss1) is an ADC Antibody targeting to dipeptidase 3 (DPEP3 or MBD3). DPEP3 is a glycosyl phosphatidylinositol anchored metallopeptidase that is overexpressed in ovarian tumors. Tamrintamab can specifically bind DPEP3-expressing cells to produce cytotoxicity. Tamrintamab can be used in ovarian cancer research ^{[1][2]} .
In Vitro	Tamrintamab is a monoclonal antibody targeting dipeptidase 3 (DPEP3 or MBD3) via a maleimide splice cleavable by protease ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Martín-Sabroso C, et al. Antibody-Antineoplastic Conjugates in Gynecological Malignancies: Current Status and Future Perspectives. *Pharmaceutics*. 2021 Oct 15;13(10):1705.

[2]. Wiedemeyer W R, et al. Abstract NT-113: SC-003, AN ANTIBODY-DRUG CONJUGATE TARGETING DIPEPTIDASE 3, EXHIBITS POTENT ANTI-TUMOR ACTIVITY IN PATIENT-DERIVED XENOGRAFT MODELS OF HIGH GRADE SEROUS OVARIAN CANCER[J]. *Clinical Cancer Research*, 2019, 25(22_Supplement): NT-113-NT-113.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA